Literature DB >> 27799164

How I treat cryoglobulinemia.

Eli Muchtar1, Hila Magen2, Morie A Gertz1.   

Abstract

Cryoglobulinemia is a distinct entity characterized by the presence of cryoglobulins in the serum. Cryoglobulins differ in their composition, which has an impact on the clinical presentation and the underlying disease that triggers cryoglobulin formation. Cryoglobulinemia is categorized into two main subgroups: type I, which is seen exclusively in clonal hematologic diseases, and type II/III, which is called mixed cryoglobulinemia and is seen in hepatitis C virus infection and systemic diseases such as B-cell lineage hematologic malignancies and connective tissue disorders. Clinical presentation is broad and varies between types but includes arthralgia, purpura, skin ulcers, glomerulonephritis, and peripheral neuropathy. Life-threatening manifestations can develop in a small proportion of patients. A full evaluation for the underlying cause is required, because each type requires a different kind of treatment, which should be tailored on the basis of disease severity, underlying disease, and prior therapies. Relapses can be frequent and can result in significant morbidity and cumulative organ impairment. We explore the spectrum of this heterogeneous disease by discussing the disease characteristics of 5 different patients.
© 2017 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27799164     DOI: 10.1182/blood-2016-09-719773

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  27 in total

Review 1.  The complexity of an overlap type resistant cryoglobulinemia: a case report and review of the literature.

Authors:  Milena Tocut; Ziv Rozman; Alexander Biro; Asher Winder; Amir Tanay; Gisele Zandman-Goddard
Journal:  Clin Rheumatol       Date:  2019-01-10       Impact factor: 2.980

2.  Cryoglobulinaemic vasculitis in light chain myeloma.

Authors:  Gwenno M Edwards; Abdulfattah Alejmi
Journal:  Clin Med (Lond)       Date:  2021-01       Impact factor: 2.659

Review 3.  How I manage monoclonal gammopathy of undetermined significance.

Authors:  Ronald S Go; S Vincent Rajkumar
Journal:  Blood       Date:  2017-11-28       Impact factor: 22.113

4.  Proliferative glomerulonephritis with unusual microlamellar organized deposits related to monoclonal immunoglobulin G3 (IgG3) kappa.

Authors:  Akiko Mii; Akira Shimizu; Daisuke Takada; Shuichi Tsuruoka
Journal:  CEN Case Rep       Date:  2018-07-09

5.  Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia.

Authors:  Surbhi Sidana; S Vincent Rajkumar; Angela Dispenzieri; Martha Q Lacy; Morie A Gertz; Francis K Buadi; Suzanne R Hayman; David Dingli; Prashant Kapoor; Wilson I Gonsalves; Ronald S Go; Yi Lisa Hwa; Nelson Leung; Amie L Fonder; Miriam A Hobbs; Steven R Zeldenrust; Stephen J Russell; John A Lust; Robert A Kyle; Shaji K Kumar
Journal:  Am J Hematol       Date:  2017-05-26       Impact factor: 10.047

6.  Clinicopathological Spectrum of Cryoglobulinemic Glomerulonephritis without Evidence of Autoimmunity Disorders: A Retrospective Study from a Single Institute of China.

Authors:  Xin Zhang; Xiao-Juan Yu; Chong-Wen An; Zi-Hao Yong; Su-Xia Wang; Fu-de Zhou; Ming-Hui Zhao
Journal:  Kidney Dis (Basel)       Date:  2022-03-25

Review 7.  Immunoglobulin M Monoclonal Gammopathies of Clinical Significance.

Authors:  Louis-Pierre Girard; Cinnie Yentia Soekojo; Melissa Ooi; Wee Joo Chng; Sanjay de Mel
Journal:  Front Oncol       Date:  2022-06-09       Impact factor: 5.738

8.  Membranous Nephropathy-Like Apolipoprotein E Deposition Disease with Apolipoprotein E Toyonaka and Homozygous Apolipoprotein E2/2 without Dyslipidemia, with Characteristic Electron-Dense Deposits.

Authors:  Akihiko Koshino; Chikako Takaeda; Takahiro Matsuno; Shinji Kitajima; Yasunori Iwata; Norihiko Sakai; Kiyotaka Nagahama; Yo Niida; Takao Saito; Hitoshi Yokoyama; Takashi Wada
Journal:  Case Rep Nephrol Dial       Date:  2022-06-10

Review 9.  Structural Basis of a Conventional Recognition Mode of IGHV1-69 Rheumatoid Factors.

Authors:  Mitsunori Shiroishi
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 10.  Understanding the Cryoglobulinemias.

Authors:  Alejandro Fuentes; Claudia Mardones; Paula I Burgos
Journal:  Curr Rheumatol Rep       Date:  2019-11-19       Impact factor: 4.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.